Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
POZN's Cash to Debt is ranked higher than
98% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. POZN: No Debt )
POZN' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.67
POZN's Equity to Asset is ranked higher than
74% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. POZN: 0.67 )
POZN' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.96
Current: 0.67

0.34
0.96
Interest Coverage No Debt
POZN's Interest Coverage is ranked higher than
81% of the 431 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. POZN: No Debt )
POZN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 10.15
M-Score: -4.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -162.60
POZN's Operating margin (%) is ranked lower than
54% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. POZN: -162.60 )
POZN' s 10-Year Operating margin (%) Range
Min: -477.51   Max: 48.51
Current: -162.6

-477.51
48.51
Net-margin (%) -161.87
POZN's Net-margin (%) is ranked lower than
54% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. POZN: -161.87 )
POZN' s 10-Year Net-margin (%) Range
Min: -472.67   Max: 48.69
Current: -161.87

-472.67
48.69
ROE (%) -93.92
POZN's ROE (%) is ranked lower than
54% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. POZN: -93.92 )
POZN' s 10-Year ROE (%) Range
Min: -618.07   Max: 40.13
Current: -93.92

-618.07
40.13
ROA (%) -47.29
POZN's ROA (%) is ranked lower than
54% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. POZN: -47.29 )
POZN' s 10-Year ROA (%) Range
Min: -280.81   Max: 34.83
Current: -47.29

-280.81
34.83
ROC (Joel Greenblatt) (%) -43035.90
POZN's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.90 vs. POZN: -43035.90 )
POZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -43035.9   Max: 40949.51
Current: -43035.9

-43035.9
40949.51
Revenue Growth (%) -46.90
POZN's Revenue Growth (%) is ranked lower than
55% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. POZN: -46.90 )
POZN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 52.4
Current: -46.9

0
52.4
» POZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

POZN Guru Trades in Q2 2013

John Rogers 3,228,236 sh (+311.99%)
Jim Simons 268,444 sh (+61.75%)
» More
Q3 2013

POZN Guru Trades in Q3 2013

John Rogers 4,379,824 sh (+35.67%)
Jim Simons 34,886 sh (-87%)
» More
Q4 2013

POZN Guru Trades in Q4 2013

Jim Simons 250,219 sh (+617.25%)
John Rogers 3,503,586 sh (-20.01%)
» More
Q1 2014

POZN Guru Trades in Q1 2014

Jim Simons 238,118 sh (-4.84%)
John Rogers 3,080,448 sh (-12.08%)
» More
» Details

Insider Trades

Latest Guru Trades with POZN



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.30
POZN's P/B is ranked higher than
50% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. POZN: 11.30 )
POZN' s 10-Year P/B Range
Min: 1.11   Max: 25.07
Current: 11.3

1.11
25.07
P/S 15.15
POZN's P/S is ranked higher than
53% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. POZN: 15.15 )
POZN' s 10-Year P/S Range
Min: 1.4   Max: 255.57
Current: 15.15

1.4
255.57
PFCF 402.50
POZN's PFCF is ranked higher than
77% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. POZN: 402.50 )
POZN' s 10-Year PFCF Range
Min: 2.45   Max: 1403
Current: 402.5

2.45
1403
EV-to-EBIT -27.45
POZN's EV-to-EBIT is ranked lower than
53% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. POZN: -27.45 )
POZN' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 727
Current: -27.45

0.1
727
Shiller P/E 77.90
POZN's Shiller P/E is ranked higher than
78% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. POZN: 77.90 )
POZN' s 10-Year Shiller P/E Range
Min: 22.94   Max: 263.33
Current: 77.9

22.94
263.33
Current Ratio 3.05
POZN's Current Ratio is ranked higher than
77% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. POZN: 3.05 )
POZN' s 10-Year Current Ratio Range
Min: 2.01   Max: 43.94
Current: 3.05

2.01
43.94
Quick Ratio 3.05
POZN's Quick Ratio is ranked higher than
81% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. POZN: 3.05 )
POZN' s 10-Year Quick Ratio Range
Min: 2.01   Max: 43.94
Current: 3.05

2.01
43.94

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.90
POZN's Price/Net Cash is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. POZN: 14.90 )
POZN' s 10-Year Price/Net Cash Range
Min: 1.14   Max: 38.45
Current: 14.9

1.14
38.45
Price/Net Current Asset Value 12.40
POZN's Price/Net Current Asset Value is ranked higher than
86% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. POZN: 12.40 )
POZN' s 10-Year Price/Net Current Asset Value Range
Min: 1.14   Max: 26.97
Current: 12.4

1.14
26.97
Price/Tangible Book 11.30
POZN's Price/Tangible Book is ranked higher than
57% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. POZN: 11.30 )
POZN' s 10-Year Price/Tangible Book Range
Min: 1.12   Max: 23.78
Current: 11.3

1.12
23.78
Price/DCF (Projected) 5.60
POZN's Price/DCF (Projected) is ranked higher than
79% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. POZN: 5.60 )
POZN' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 33.33
Current: 5.6

0.53
33.33
Price/Median PS Value 2.00
POZN's Price/Median PS Value is ranked higher than
56% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. POZN: 2.00 )
POZN' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 32.29
Current: 2

0.18
32.29
Earnings Yield (Greenblatt) 29.50
POZN's Earnings Yield (Greenblatt) is ranked higher than
96% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.00 vs. POZN: 29.50 )
POZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1372.1
Current: 29.5

0.1
1372.1
Forward Rate of Return (Yacktman) 0.17
POZN's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. POZN: 0.17 )
POZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9   Max: 5.4
Current: 0.17

-9
5.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PZ6.Germany
POZEN Inc., is incorporated in the state of Delaware on September 25, 1996. It operates as a pharmaceutical company focused on developing products which could provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain and pain related conditions. The Company has developed Treximet in collaboration with GlaxoSmithKline. Treximet is the brand name for the product combining sumatriptan 85 mg, formulated with RT Technology and naproxen sodium 500 mg in a single tablet designed for the acute treatment of migraine. Treximet incorporates its MT 400 technology, which refers to its proprietary combinations of a triptan (5-HT1B/1D agonist) and a non-steroidal anti-inflammatory drug, or NSAID. Under its MT 400 technology, it seeks to develop product candidates that provide acute migraine therapy by combining the activity of two drugs that act by different mechanisms to reduce the pain and associated symptoms of migraine. It is developing product candidates that combine a type of acid inhibitor, a proton pump inhibitor, with an NSAID. These product candidates plan to provide management of pain and inflammations associated with conditions such as osteoarthritis, and are intended to have fewer gastrointestinal complications compared to an NSAID taken alone. It has also developed VIMOVO with AstraZeneca AB, or AstraZeneca. VIMOVO (formerly referred to as PN 400) is the brand name for a proprietary fixed dose combination of the PPI esomeprazole magnesium with the NSAID naproxen in a single tablet. On April 30, 2010, the FDA approved VIMOVO for the relief of the signs and symptoms of osteoarthritis ("OA"), rheumatoid arthritis ("RA") and ankylosing spondylitis ("AS") and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. The competition for VIMOVO comes from the oral anti-arthritic market, or more specifically the traditional non-selective NSAIDs (such as naproxen and diclofenac), traditional NSAID/gastroprotective agent combination products or combination product packages (such as Arthrotec and Prevacid NapraPACTM ) and the only remaining COX-2 inhibitor, Celebrex. Therapeutic product candidates for human use are subject to rigorous preclinical and clinical testing and other requirements of the Federal Food, Drug and Cosmetic Act, or FFDCA, implemented by the FDA, as well as similar statutory and regulatory requirements of foreign countries.
» More Articles for POZN

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: AR, CSCO, SUTR, POZN, JAH May 27 2014 
Guru Weekly Real Time Update Jul 12 2013 
John Rogers Makes 5 Real-Time Increases Jul 11 2013 
John Rogers' May Commentary - What's Attractive and New Buys Jun 13 2013 
comment on POZN Nov 13 2012 
Pozen Inc. Reports Operating Results (10-K) Mar 10 2011 
Pozen Inc. Reports Operating Results (10-Q) Oct 29 2010 
Pozen Inc. Reports Operating Results (10-Q) Aug 05 2010 
Pozen Inc. Reports Operating Results (10-Q) Apr 29 2010 
Pozen Inc. Reports Operating Results (10-Q) Nov 02 2009 

More From Other Websites
Nasdaq stocks posting largest percentage increases Jul 23 2014
Why POZEN (POZN) Stock Is Tanking Today Jul 16 2014
POZEN Announces FDA Acceptance of Refiling of New Drug Application for PA8140/PA32540 Tablets Jul 16 2014
POZEN INC /NC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 16 2014
POZEN Announces FDA Acceptance of Refiling of New Drug Application for PA8140/PA32540 Tablets Jul 16 2014
Pozen Resubmits PA NDA, PDUFA In Two Months? Jul 03 2014
POZEN Resubmits PA8140/PA32540 NDA Jul 01 2014
POZEN INC /NC Files SEC form 8-K, Other Events Jul 01 2014
POZEN INC /NC Files SEC form 8-K, Other Events Jun 26 2014
Alcobra Ltd. (ADHD) Jumps: Stock Rises 8.7% Jun 12 2014
POZEN INC /NC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 09 2014
POZEN INC /NC Financials May 16 2014
Aura Of Light Shines On Pernix Shares Following Treximet Acquisition May 14 2014
Pernix says Treximet has four Orange Book patents May 14 2014
POZEN Update Call scheduled for 11:00 am ET today May 14 2014
POZEN to host conference call May 14 2014
POZEN INC /NC Files SEC form 8-K, Entry into a Material Definitive Agreement May 14 2014
POZEN says U.S. rights for Treximet to be acquired by Pernix Therapeutics May 14 2014
Pernix Therapeutics to make $3M payment to CPPIB Credit Investments May 14 2014
Pernix Therapeutics to acquire TREXIMET tablets for migrain from GlaxoSmithKline May 14 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide